Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates
© 2022. The Author(s)..
Emerging SARS-CoV-2 variants and the gradually decreasing neutralizing antibodies over time post vaccination have led to an increase in incidents of breakthrough infection across the world. To investigate the potential protective effect of the recombinant protein subunit COVID-19 vaccine targeting receptor-binding domain (RBD) (PS-RBD) and whole inactivated virus particle vaccine (IV) against the variant strains, in this study, rhesus macaques were immunized with PS-RBD or IV vaccine, followed by a Beta variant (B.1.351) challenge. Although neutralizing activity against the Beta variant was reduced compared with that against the prototype, the decreased viral load in both upper and lower respiratory tracts, milder pathological changes, and downregulated inflammatory cytokine levels in lung tissues after challenge demonstrated that PS-RBD and IV still provided effective protection against the Beta variant in the macaque model. Furthermore, PS-RBD-induced macaque sera possessed general binding and neutralizing activity to Alpha, Beta, Delta, and Omicron variants in our study, though the neutralizing antibody (NAb) titers declined by varying degrees, demonstrating potential protection of PS-RBD against current circulating variants of concern (VOCs). Interestingly, although the IV vaccine-induced extremely low neutralizing antibody titers against the Beta variant, it still showed reduction for viral load and significantly alleviated pathological change. Other correlates of vaccine-induced protection (CoP) like antibody-dependent cellular cytotoxicity (ADCC) and immune memory were both confirmed to be existing in IV vaccinated group and possibly be involved in the protective mechanism.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Signal transduction and targeted therapy - 7(2022), 1 vom: 03. März, Seite 69 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
He, Qian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 14.03.2022 Date Revised 14.03.2022 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41392-022-00926-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337728496 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337728496 | ||
| 003 | DE-627 | ||
| 005 | 20231225235057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41392-022-00926-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337728496 | ||
| 035 | |a (NLM)35241645 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a He, Qian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2022 | ||
| 500 | |a Date Revised 14.03.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Emerging SARS-CoV-2 variants and the gradually decreasing neutralizing antibodies over time post vaccination have led to an increase in incidents of breakthrough infection across the world. To investigate the potential protective effect of the recombinant protein subunit COVID-19 vaccine targeting receptor-binding domain (RBD) (PS-RBD) and whole inactivated virus particle vaccine (IV) against the variant strains, in this study, rhesus macaques were immunized with PS-RBD or IV vaccine, followed by a Beta variant (B.1.351) challenge. Although neutralizing activity against the Beta variant was reduced compared with that against the prototype, the decreased viral load in both upper and lower respiratory tracts, milder pathological changes, and downregulated inflammatory cytokine levels in lung tissues after challenge demonstrated that PS-RBD and IV still provided effective protection against the Beta variant in the macaque model. Furthermore, PS-RBD-induced macaque sera possessed general binding and neutralizing activity to Alpha, Beta, Delta, and Omicron variants in our study, though the neutralizing antibody (NAb) titers declined by varying degrees, demonstrating potential protection of PS-RBD against current circulating variants of concern (VOCs). Interestingly, although the IV vaccine-induced extremely low neutralizing antibody titers against the Beta variant, it still showed reduction for viral load and significantly alleviated pathological change. Other correlates of vaccine-induced protection (CoP) like antibody-dependent cellular cytotoxicity (ADCC) and immune memory were both confirmed to be existing in IV vaccinated group and possibly be involved in the protective mechanism | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Inactivated |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 700 | 1 | |a Mao, Qunying |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Xiaozhong |e verfasserin |4 aut | |
| 700 | 1 | |a He, Zhanlong |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Shuaiyao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jialu |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Bian, Lianlian |e verfasserin |4 aut | |
| 700 | 1 | |a An, Chaoqiang |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Wenhai |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Fengmei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yanan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yanyan |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Yadi |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Xujia |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Jinghuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Xing |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Weijin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Changgui |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Junzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Zhenglun |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Miao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Signal transduction and targeted therapy |d 2016 |g 7(2022), 1 vom: 03. März, Seite 69 |w (DE-627)NLM257871861 |x 2059-3635 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2022 |g number:1 |g day:03 |g month:03 |g pages:69 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41392-022-00926-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2022 |e 1 |b 03 |c 03 |h 69 | ||